| 谭张森,陈欣祎,李尚日.外周血指标对免疫检查点抑制剂治疗头颈部鳞状细胞癌患者预后的预测作用[J].肿瘤学杂志,2024,30(5):386-393. |
| 外周血指标对免疫检查点抑制剂治疗头颈部鳞状细胞癌患者预后的预测作用 |
| Predicting Value of Peripheral Blood Indicators for Patients with Head and Neck Squamous Cell Carcinoma Undergoing Immunotherapy |
| 投稿时间：2024-03-04 |
| DOI：10.11735/j.issn.1671-170X.2024.05.B006 |
|
 |
| 中文关键词: 头颈部鳞状细胞癌 免疫检查点抑制剂 外周血指标 无进展生存期 预后模型 |
| 英文关键词:head and neck squamous cell carcinoma immune checkpoint inhibitors peripheral blood indicators progression-free survival prognostic model |
| 基金项目: |
|
| 摘要点击次数: 206 |
| 全文下载次数: 123 |
| 中文摘要: |
| 摘 要：［目的］评估外周血指标对头颈部鳞状细胞癌（head and neck squamous cell carcinoma，HNSCC）患者接受免疫检查点抑制剂治疗后预后的预测价值。［方法］ 回顾性收集接受免疫检查点抑制剂治疗的HNSCC患者117例的临床和生存数据。使用X-tile确定基线和治疗2个周期后乳酸脱氢酶（lactate dehydrogenase，LDH）、纤维蛋白原（fibrinogen，FIB）和衍生中性粒细胞-淋巴细胞比值（derived neutrophil lymphocyte ratio，dNLR）、纤维蛋白原与白蛋白比值（fibrinogen to albumin ratio，FAR）和预后营养指数（prognostic nutritional index，PNI）最佳截断值。使用Kaplan-Meier方法进行生存分析，并利用Cox比例风险回归模型进行单因素和多因素分析。根据多变量分析结果构建预后评分模型的预后列线图。［结果］ HNSCC患者接受免疫检查点抑制剂治疗后，疾病控制率为87.2%，客观缓解率为44.4%。对免疫检查点抑制剂有应答患者的基线LDH、FIB和dNLR水平显著性降低（P均<0.05）。生存分析显示，基线LDH>231 U/L（χ2=5.537，P=0.019）、基线FIB> 4.4 ng/mL(χ2=7.409，P=0.006)和基线FAR> 0.11(χ2=5.144，P=0.023）患者具有较短的无进展生存期。接受免疫一线治疗相比较于二线、三线治疗显示出更好的无进展生存期（8.2个月 vs 7.7个月 vs 4.5个月，χ2=6.195，P=0.045）。多因素回归分析显示免疫治疗线数、淋巴结转移及基线LDH水平是影响患者无进展生存期的独立预后因素，纳入构建预后列线图，该模型C指数为0.662。经过2个免疫治疗周期后，FIB≤4.47（8.8个月 vs 6.0个月，χ2=4.216，P=0.040）、dNLR≤1.56（9.2 个月vs 7.2个月，χ2=4.572，P=0.032）和PNI>44.1（8.2个月 vs 5.5 个月，χ2=4.068，P=0.044）与较长的PFS相关联。［结论］ 基线LDH、FIB和FAR水平与PFS密切相关。动态变化分析显示，LDH、FIB、FAR和PNI在疾病进展时出现显著性变化。外周血指标可作为接受免疫治疗的HNSCC患者的预后因素，并为个体化治疗提供了依据。 |
| 英文摘要: |
| Abstract： ［Objective］ To evaluate the predictive value of peripheral blood indicators for the prognosis of patients with head and neck squamous cell carcinoma(HNSCC) undergoing immune checkpoint inhibitors(ICIs) therapy. ［Methods］ Clinical and survival data of 117 patients with HNSCC undergoing ICIs therapy were retrospectively analyzed. The optimal cut-off values of lactate dehydrogenase(LDH)， fibrinogen(FIB)， fibrinogen to albumin ratio(FAR)， derived neutrophil lymphocyte ratio(dNLR) and prognostic nutritional index(PNI) at baseline and after 2 cycles of treatment were determined with X-tile software. Kaplan-Meier method was employed for survival analysis， and univariate and multivariate Cox proportional hazards regression model was used to examine the predicting factors of survival. A prognostic nomogram was constructed based on the results of multivariate analysis. ［Results］ After ICIs therapy， the disease control rate was 87.2%， and the objective response rate was 44.4%. Baseline levels of LDH， FIB， and dNLR were significantly lower in patients responding to ICIs(P all <0.05). Survival analysis revealed that patients with baseline LDH > 231 U/L（χ2=5.537， P=0.019）， FIB>4.4 ng/mL(χ2=7.409， P=0.006) and FAR>0.11(χ2=5.144， P=0.023） had shorter progression-free survival(PFS). Patients receiving first-line immunotherapy showed better PFS compared to second-line and beyond(8.2 vs 7.7 vs 4.5 months， χ2=6.195， P=0.045). Multivariate regression analysis showed the number of immune therapy lines， lymph node metastasis and baseline LDH were independent prognostic factors for PFS. A prognostic nomogram was constructed with a C-index of 0.662. After two cycles of immune therapy， FIB ≤4.47（8.8 vs 6.0 months， χ2=4.216， P=0.040）， dNLR≤1.56（9.2 vs 7.2 months， χ2=4.572， P=0.032） and PNI>44.1（8.2 vs 5.5 months， χ2=4.068， P=0.044） were associated with longer PFS. ［Conclusion］ Baseline levels of LDH， FIB and FAR are closely associated with PFS of HNSCC patients receiving immunotherapy. Dynamic changes analysis reveals significant alterations in LDH， FIB， FAR and PNI at disease progression. Peripheral blood indicators can be used as prognostic factors for HNSCC patients receiving immunotherapy， which provides the basis for individualized treatment. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |